Changes in expression of T-helper (Th) 1- and Th2-associated chemokine receptors on peripheral blood lymphocytes and plasma concentrations of their ligands, interferon-inducible protein-10 and thymus and activation-regulated chemokine, after antithyroid drug administration in hyperthyroid patients with Graves' disease

European Journal of Endocrinology

Volumn 156, Issue 6, 2007, Pages 623-630

  Inukai, Yoshihisa ^b   Momobayashi, Atsushi ^a   Sugawara, Naoto ^a   Aso, Yoshimasa ^b  

^a LSI MEDIENCE CORPORATION   (Japan)

^b DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHYROID AGENT; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CXCR3; GAMMA INTERFERON INDUCIBLE PROTEIN 10; THIAMAZOLE; THYMUS AND ACTIVATION REGULATED CHEMOKINE;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CELL COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; FEMALE; FLOW CYTOMETRY; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; MALE; OUTPATIENT CARE; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TH1 CELL; TH2 CELL;

ADULT; ANTITHYROID AGENTS; BIOLOGICAL MARKERS; CHEMOKINES, CC; CHEMOKINES, CXC; FEMALE; FLOW CYTOMETRY; GRAVES DISEASE; HUMANS; LIGANDS; MALE; METHIMAZOLE; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, CHEMOKINE; TH1 CELLS; TH2 CELLS; THYMUS GLAND;

EID: 34250786977     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/EJE-07-0019     Document Type: Article

References (31)

1. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA & Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. Journal of Immunology 1986 136 2348-2357.
2. Mosmann TR & Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annual Review of Immunology 1989 7 145-173.
3. Nicholson LB & Kuchroo VK. Manipulation of the Th1/Th2 balance in autoimmune disease. Current Opinion in Immunology 1996 8 837-842.
4. Weetman AP. Graves' disease. New England Journal of Medicine 2000 343 1236-1248.
5. Mullins RJ, Cohen SB, Webb LM, Chernajovsky Y, Dayan CM, Londei M & Feldmann M. Identification of thyroid stimulating hormone rcceptor-specific T cells in Graves' disease thyroid using autoantigen-transfected Epstein-Barr virus-transformed B cell lines. Journal of Clinical Investigation 1995 96 30-37.
6. Kallmann BA, Huther M, Tubes M, Feldkamp J, Bertrams J, Gries FA, Lampeter EF & Kolb H. Systemic bias of cytokine production toward cell-mediated immune regulation in IDDM and toward humoral immunity in Graves' disease. Diabetes 1997 46 237-243.
7. Nagayama Y, Mizuguchi H, Hayakawa T, Niwa M, McLachlan SM & Rapoport B. Prevention of autoantibody-mediated Graves'-like hyperthyroidism in mice with IL-4, a Th2 cytokine. Journal of Immunology 2003 170 3522-3527.
8. McLachlan SM, Nagayama Y & Rapoport B. Insight into Graves' hyperthyroidism from animal models. Endocrine Reviews 2005 26 800-832.
9. Luster AD. Chemokines-chemotactic cytokines that mediate inflammation. New England Journal of Medicine 1998 338 436-445.
10. Qin S, Rottman JB, Myers P Kassarn N, Weinblatt M, Loetscher M, Koch AE, Moser B & Mackay CR. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. Journal of Clinical Investigation 1998 101 746-754.
11. Bonecchi R, Bianchi G, Bordignon PP, D'Ambrosio D, Lang R, Borsatti A, Sozzani S, Allavena P, Gray PA, Mantovani A & Sinigaglia F. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. Journal of Experimental Medicine 1998 187 129-134.
12. Romagnani F, Rotondi M, Lazzeri E, Lasagni L, Francalanci M, Buonamano A, Milani S, Vitti F, Chiovato L, Tonacchera M, Bellastella A & Serio M. Expression of IP-10/CXCL10 and MIG/CXCL9 in the thyroid and increased levels of IP-10/CXCL10 in the serum of patients with recent-onset Graves' disease. American Journal of Pathology 2002 161 195-206.
13. Garcia-Lopez MA, Sancho D, Sanchez-Madrid F & Marazuela M. Thyrocytes from autoimmune thyroid disorders produce the chemokines IP-10 and Mig and attract CXCR3+ lymphocytes. Journal of Clinical Endocrinology and Metabolism 2001 86 5008-5016.
14. Antonelli A, Fallahi P, Rotondi M, Ferrari SM, Romagnani P, Grosso M, Ferrannini E & Serio M. Increased serum CXCL10 in Graves' disease or autoimmune thyroiditis is not associated with hyper- or hypothyroidism per se, but is specifically sustained by the autoimmune, inflammatory process. European Journal of Endocrinology 2006 154 651-658.
15. Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari SM, Barani L, Ferrannini E & Serio, M. Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy. Clinical Endocrinology 2006 64 189-195.
16. Aso Y, Matsuura H, Momobayashi A, Inukai Y, Sugawara N, Nakano T, Yamamoto R, Wakabayashi S, Takebayashi K & Inukai T. Profound reduction in T-helper (Th) 1 lymphocytes in peripheral blood from patients with concurrent type 1 diabetes and Graves' disease. Endocrine Journal 2006 53 377-385.
17. Kemp EH, Metcalfe RA, Smith KA, Woodroofe MN, Watson PF & Weetman AP. Detection and localization of chemokine gene expression in autoimmune thyroid disease. Clinical Endocrinology 2003 59 207-213.
18. Antonelli A, Fallahi P, Rotondi M, Ferrari SM, Serio M & Miccoli P. Serum levels of the interferon-gamma-inducible alpha chemokine CXCL10 in patients with active Graves'disease, and modulation by methimazole therapy and thyroidectomy. British Journal of Surgery 2006 93 1226-1231.
19. Antonelli A, Rotondi M, Fallahi P, Grosso M, Boni G, Ferrari SM, Romagnani P, Serio M, Mariani G & Ferrannim E. Iodine-131 given for therapeutic purposes modulates differently interferon-gamma inducible alpha chemokine CXCL10 serum levels in patients with active Graves' disease or with toxic nodular goiter. Journal of Clinical Endocrinology and Metabolism 2007 92 1485-1490.
20. Sugawara N, Yamashita T, Ote Y, Miura M, Terada N & Kurosawa M. TARC in allergic disease. Allergy 2002 57 180-181.
21. Leung TF, Wong CK, Chan IH, Ip WK, Lam CW & Wong GW. Plasma concentration of thymus and activation-regulated chemokine is elevated in childhood asthma. Journal of Allergy and Clinical Immunology 2002 110 404-409.
22. Nakatani T, Kaburagi Y, Shimada Y, Inaoki M, Takehara K, Mukaida N & Sato S. CCR4 memory CD4+T lymphocytes are increased in peripheral blood and lesional skin from patients with atopic dermatitis. Journal of Allergy and Clinical Immunology 2001 107 353-358.
23. Aust G, Sittig D, Steinert M, Lamesch P & Lohmann T. Graves' disease is associated with an altered CXCR3 and CCR5 expression in thyroid-derived compared to peripheral blood lymphocytes. Clinical and Experimental Immunology 2002 127 479-485.
24. Aniszewski JP, Valyasevi RW & Balm RS. Relationship between disease duration and predominant orbital T cell subset in Graves' ophthalmopathy. Journal of Clinical Endocrinology and Metabolism 2000 85 776-780.
25. Antonelli A, Rotondi M, Ferrari SM, Fallahi P, Romagnani P, Franceschini SS, Serio M & Ferrannini F. Interferon-gamma-inducible alpha-chemokine CXCL10 involvement in Graves' ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. Journal of Clinical Endocrinology and Metabolism 2006 91 614-620.
26. Weetman AP. Cellular immune responses in autoimmune thyroid disease. Clinical Endocrinology 2004 61 405-413.
27. Gessl A, Wilfing A, Agis H, Steiner G, Czernin S, Boltz-Nitulescu G, Vierhapper H & Waldhausl W. Activated naive CD4+ peripheral blood T cells in autoimmune thyroid disease. Thyroid 1995 5 117-125.
28. Ciampolillo A, Guastamacchia E, Amati L, Magrone T, Munno I, Jirillo E, Triggiani V, Fallacara R & Tafaro E. Modifications of the immune responsiveness in patients with autoimmune thyroiditis: evidence for a systemic immune alteration. Current Pharmaceutical Design 2003 9 1946-1950.
29. Mazziotti G, Sorviflo E Naclerio C, Farzati A, Cioffi M, Perna R, Valentini G, Farzati B, Amato G & Carella C. Type-1 response in peripheral CD4+ and CD8+ T cells from patients with Hashimoto's thyroiditis. European Journal of Endocrinology 2003 148 383-388.
30. Cooper DS. Antithyroid drugs. New England Journal of Medicine 2005 352 905-917.
31. Totterman TH, Karlsson EA, Bengtsson M & Mendel-Hartvig I. Induction of circulating activated suppressor-like T cells by methimazole therapy for Graves' disease. New England Journal of Medicine 1987 316 15-22.